MyoPax's breakthrough regenerative cell product for Exstrophy-Epispadias Complex earns Rare Pediatric Disease Designation
The U.S. Food and Drug Administration (FDA) has granted MyoPax, a young European biotech start-up, a Rare Pediatric Disease Designation (RPDD) for their innovative regenerative cell therapies. MyoPax focuses on developing treatments for debilitating muscle disorders, and the RPDD specifically applies to a congenital muscle defect associated with Exstrophy-Epispadias Complex (EEC). This recognition by the FDA highlights the potential of MyoPax's patented technology to provide a unique therapeutic approach for patients affected by this rare condition. Furthermore, the RPDD offers regulatory and financial incentives that aim to accelerate the development of new therapies for rare diseases primarily affecting children.
To advance their research, MyoPax is preparing for expansion into the United States. Meanwhile, the first clinical trial for treating EEC (registered under NCT04729582) will take place in Germany under the sponsorship of Charité – Universitätsmedizin Berlin. The trial will receive funding from the German Federal Ministry of Education and Research, as well as the ForTra gGmbH of the Else-Kröner-Fresenius Foundation. This trial is crucial in addressing the urgency and importance of developing a transformative treatment for EEC and other muscle disorders, as the current available therapies are only supportive and leave many patients with significant challenges.
EEC is a rare congenital malformation of the genital and urinary organs, affecting approximately one in 11,000 individuals. The current treatment approach involves multiple reconstructive surgeries and lifelong management. However, it is often unable to fully correct the defined sphincter muscle defect, resulting in persistent urinary incontinence.
In the United States, a rare pediatric disease is defined by the Federal Food, Drug, and Cosmetic Act as a serious or life-threatening condition that affects individuals under the age of 18 and has a prevalence of fewer than 200,000 people. Recognizing the difficulties faced by pharmaceutical companies in developing treatments for these patient populations, Congress reauthorized the Creating Hope Act in 2020. This act enables companies to receive a Priority Review Voucher (PRV) upon the approval of a product with a RPDD. The PRV can be utilized to expedite the review process of a marketing application for a different product candidate, or it can be sold or transferred to another sponsor, providing an additional incentive for companies to invest in rare pediatric diseases.
